TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,161,213 | -31.1% | 1,807,742 | +18.3% | 0.43% | -22.4% |
| Q2 2023 | $23,465,779 | -18.3% | 1,527,720 | +19.7% | 0.56% | -18.5% |
| Q1 2023 | $28,711,859 | +43.5% | 1,276,650 | +34.2% | 0.68% | +42.1% |
| Q4 2022 | $20,013,200 | -14.7% | 951,650 | 0.0% | 0.48% | -20.5% |
| Q3 2022 | $23,449,000 | +1.7% | 951,650 | 0.0% | 0.61% | -9.7% |
| Q2 2022 | $23,058,000 | -6.0% | 951,650 | 0.0% | 0.67% | +8.8% |
| Q1 2022 | $24,524,000 | -17.0% | 951,650 | 0.0% | 0.62% | -9.5% |
| Q4 2021 | $29,539,000 | -18.6% | 951,650 | -36.4% | 0.68% | -10.6% |
| Q3 2021 | $36,298,000 | +66.5% | 1,496,817 | +0.2% | 0.76% | +77.0% |
| Q2 2021 | $21,800,000 | -40.8% | 1,494,164 | +1.3% | 0.43% | -46.4% |
| Q1 2021 | $36,845,000 | +32.4% | 1,475,564 | +44.5% | 0.80% | +36.3% |
| Q4 2020 | $27,827,000 | – | 1,021,000 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |